Image

Global Sinusitis Treatment Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Sinusitis Treatment Drugs Market, By Type (Acute Sinusitis, Sub-Acute Sinusitis, Chronic Sinusitis), Treatment (Analgesics, Antihistamines, Corticosteroids, Antibiotics, Sulphonamides, Other), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Sinusitis Treatment Drugs Market

Sinusitis Treatment Drugs Market Analysis and Size

The global sinusitis treatment drugs market is expected to witness significant growth during the forecast period. The majority of sinus infections are stated to be caused by common cold and viral infections. These infections are classified as chronic and acute based on THE level of severity. Since sinus infection and COVID-19 have parallel symptoms, there is an urgent need to distinguish between the two.  Sinusitis affects approximately 40% of the U.S. population, with yearly treatment costs of $ 8.6 million. Such increasing prevalence particularly among the urban population, has been the major driving factor.

 Data Bridge Market Research analyses a growth rate in the global sinusitis treatment drugs market in the forecast period 2022-2029. The expected CAGR of g global sinusitis treatment drugs market is tend to be around 3.50% in the mentioned forecast period. The market was valued at USD 3.03 billion in 2021, and it would grow upto USD 3.99 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.       

Sinusitis Treatment Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Acute Sinusitis, Sub-Acute Sinusitis, Chronic Sinusitis), Treatment (Analgesics, Antihistamines, Corticosteroids, Antibiotics, Sulphonamides, Other), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), AstraZeneca (U.K.), Regeneron Pharmaceuticals Inc (U.S.), OptiNose US, Inc (U.S.)

Market Opportunities

  • Improved Intra-nasal Drug Delivery
  • Approval From Regulatory Bodies

Market Definition

Sinusitis is also known as sinus infection and it is a condition wherein the tissues lines the sinuses became inflamed or swelled. It is mostly triggered by common cold or allergies. Symptoms include nasal congestion, headache or facial pain, rhinorrhea and others. Facial pain in sinusitis is the most common symptom. Acute sinusitis generally is caused by virus and effective method of treatment were nasal irrigation. For chronic sinusitis, patients were recommended with antibiotics, topical and corticosteroids, and other medications.  

Global Sinusitis Treatment Drugs Market Dynamics

Drivers

  • Increasing Prevalence of Sinusitis

The incidence of sinus infection among adults and children is rising. Among the most common of triggering sinus infection in adults is the history of respiratory tract infections, compromised immunity, structural issues in sinuses, and nasal polyps. Sinusitis can be caused in children by using a pacifier, a day-care, feeding while lying down, and second-hand contact to smoke. Thus, the increasing occurrence of sinusitis is boosting the growth of the sinusitis treatment drugs market.

  • High Demand for nasal sprays

The unique nasal spray designs are a fast rising phenomenon in the global sinusitis treatment drugs market. Innovators are gaining attentiveness that investors need to go beyond drug innovations and focus more on different ways to deliver it in hard-to-reach cavities of the patients’ sinuses. For instance, the Optinose XHANCE is gaining approval for overcoming this challenge and developing a nasal spray that patients can use at the comfort of their home. 

Opportunities

  • Improved Intra-nasal Drug Delivery

The high incidence of sinusitis in the U.S. is creating beneficial revenue opportunities for companies in the sinusitis treatment drugs market. For instance, Nasus Medical, a startup born out of Stanford Biodesign and now a Fogarty Institute Company is building incremental opportunities by developing a solution for improved intra-nasal drug delivery. Major market players are taking advantages from such innovations to develop new advanced devices that allow patients to treat themselves at home to diminish symptoms of sinusitis in its early stages. This improves the quality of life of patients. This creates more opportunity for the market growth.

  • Approval From Regulatory Bodies

Rising recommendation from regulatory bodies for approval of the new drug used in the treatment of nasal polyps, is expected to drive the growth of global sinusitis treatment drugs market, over the forecast period. For instance, In Aug 2020, Xolair from Novartis received approval from the European Commission in the form of an add-on therapy along with corticosteroids for treating chronic rhinosinusitis with the nasal polyps. In addition to this, in Aug 2020, Satsuma Pharmaceuticals, Inc. declared initiation on the part of enrolment of patients in ASCEND trial. It is a multi-centre, 12-month, open-label study for assessing tolerability and safety of STS101.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified healthcare professionals who are unable to treat these patients with appropriate treatments could curb the growth of the global sinusitis treatment drugs market over a forecast period.

  • High Cost

The huge expenditure associated with the treatment of sinusitis hamper the market growth as it involves the high-end drug types such as analgesics, antihistamines, corticosteroids.  

This global sinusitis treatment drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global sinusitis treatment drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Sinusitis Treatment Drugs Market

Sinus infection and COVID-19 have parallel symptoms, thus there is a need to distinguish between the two. Investors in the sinusitis treatment market are surging awareness that coronavirus is related with some of the major symptoms such as dry cough, whereas sinus is linked with cough involving mucus. As such, there is not enough evidence whether COVID-19 causes sinusitis.

The symptoms of sinus overlap with that of COVID-19, shareholders in the sinusitis treatment market are growing awareness about telemedicine and e-health to decrease the load on healthcare professionals and reduce clinical visits. Digital consultations are mounting rapidly among individuals living in urban cities. Investors in the value chain are drawing future growth opportunities in telemedicine to increase its penetration in rural regions.

Global Sinusitis Treatment Drugs Market Scope

The global sinusitis treatment drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Acute Sinusitis
  • Sub-Acute Sinusitis
  • Chronic Sinusitis

Treatment

  • Analgesics
  • Antihistamines
  • Corticosteroids
  • Antibiotics
  • Sulphonamides
  • Other

Route of Administration

  • Oral
  • Topical
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Sinusitis Treatment Drugs Market Regional Analysis/Insights

The global sinusitis treatment drugs market is analysed and market size insights and trends are provided by type, treatment,  route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global sinusitis treatment drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global sinusitis treatment drugs market throughout the forecasted period due to the increasing awareness about the diseases and rapid growth in bacterial as well as viral diseases.

North America dominates the market due to the high-income of the countries, vulnerable sinusitis population and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Sinusitis Treatment Drugs Market Share Analysis

The global sinusitis treatment drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global sinusitis treatment drugs market

Key players operating in the global sinusitis treatment drugs market include:

  • Pfizer Inc.(U.S.)
  • Merck KGaA (Germany)
  • Sanofi (France)
  • Biocare Medical, LLC (U.S.)
  • Lilly (U.S.)
  • Teva Pharmaceutical Industries (Israel)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • AstraZeneca (U.K.)
  • Regeneron Pharmaceuticals Inc (U.S.)
  • OptiNose US, Inc (U.S.)


SKU-
Why Choose Us


Frequently Asked Questions

The Sinusitis Treatment Drugs Market is projected to grow at a CAGR of 3.50% during the forecast period by 2029.
The future market value of the Sinusitis Treatment Drugs Market is expected to reach USD 3.99 billion by 2029.
The major players in the Sinusitis Treatment Drugs Market are Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), AstraZeneca (U.K.), Regeneron Pharmaceuticals Inc (U.S.), OptiNose US, Inc (U.S.)
The country covered in the Sinusitis Treatment Drugs Market are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, etc.